These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 30047303)

  • 1. In silico guided development of imine-based inhibitors for resistance-deriving kinases.
    Kumar Singh P; Silakari O
    J Biomol Struct Dyn; 2019 Jul; 37(10):2593-2599. PubMed ID: 30047303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular dynamics guided development of indole based dual inhibitors of EGFR (T790M) and c-MET.
    Singh PK; Silakari O
    Bioorg Chem; 2018 Sep; 79():163-170. PubMed ID: 29758406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- d]pyrimidine-2,4(1 H,3 H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.
    Hao Y; Lyu J; Qu R; Tong Y; Sun D; Feng F; Tong L; Yang T; Zhao Z; Zhu L; Ding J; Xu Y; Xie H; Li H
    J Med Chem; 2018 Jul; 61(13):5609-5622. PubMed ID: 29906114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
    Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
    Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure based designing of triazolopyrimidone-based reversible inhibitors for kinases involved in NSCLC.
    Singh PK; Chaudhari D; Jain S; Silakari O
    Bioorg Med Chem Lett; 2019 Jul; 29(13):1565-1571. PubMed ID: 31078412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Staurosporine scaffold-based rational discovery of the wild-type sparing reversible inhibitors of EGFR T790M gatekeeper mutant in lung cancer with analog-sensitive kinase technology.
    Song X; Liu X; Ding X
    J Mol Recognit; 2017 Apr; 30(4):. PubMed ID: 27891677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel drug-resistant EGFR mutant inhibitors by in silico screening using comprehensive assessments of protein structures.
    Sato T; Watanabe H; Tsuganezawa K; Yuki H; Mikuni J; Yoshikawa S; Kukimoto-Niino M; Fujimoto T; Terazawa Y; Wakiyama M; Kojima H; Okabe T; Nagano T; Shirouzu M; Yokoyama S; Tanaka A; Honma T
    Bioorg Med Chem; 2012 Jun; 20(12):3756-67. PubMed ID: 22607878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel EGFR (T790M)-cMET dual inhibitors: putative therapeutic agents for non-small-cell lung cancer.
    Singh PK; Silakari O
    Future Med Chem; 2017 Apr; 9(5):469-483. PubMed ID: 28362115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3D-QSAR-aided design of potent c-Met inhibitors using molecular dynamics simulation and binding free energy calculation.
    Balasubramanian PK; Balupuri A; Bhujbal SP; Cho SJ
    J Biomol Struct Dyn; 2019 May; 37(8):2165-2178. PubMed ID: 30044205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer.
    Yi Y; Wang L; Zhao D; Huang S; Wang C; Liu Z; Sun H; Liu K; Ma X; Li Y
    Chem Biol Drug Des; 2018 Dec; 92(6):1988-1997. PubMed ID: 30030903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy-Resistant L858R/T790M/C797S Mutant.
    Günther M; Juchum M; Kelter G; Fiebig H; Laufer S
    Angew Chem Int Ed Engl; 2016 Aug; 55(36):10890-4. PubMed ID: 27466205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico evaluation, molecular docking and QSAR analysis of quinazoline-based EGFR-T790M inhibitors.
    Asadollahi-Baboli M
    Mol Divers; 2016 Aug; 20(3):729-39. PubMed ID: 27209475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition.
    Patel H; Pawara R; Surana S
    Comput Biol Chem; 2018 Jun; 74():167-189. PubMed ID: 29627693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors.
    Xiao Q; Qu R; Gao D; Yan Q; Tong L; Zhang W; Ding J; Xie H; Li Y
    Bioorg Med Chem; 2016 Jun; 24(12):2673-80. PubMed ID: 27131639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
    Iqbal S; Anantha Krishnan D; Gunasekaran K
    J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-Based Drug Design Studies Toward the Discovery of Novel Chalcone Derivatives as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors.
    Al-Anazi M; Al-Najjar BO; Khairuddean M
    Molecules; 2018 Dec; 23(12):. PubMed ID: 30563058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle.
    Patel HM; Pawara R; Ansari A; Noolvi M; Surana S
    Bioorg Med Chem; 2017 May; 25(10):2713-2723. PubMed ID: 28366268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and evaluation of A-ring-modified lamellarin N analogues as noncovalent inhibitors of the EGFR T790M/L858R mutant.
    Fukuda T; Umeki T; Tokushima K; Xiang G; Yoshida Y; Ishibashi F; Oku Y; Nishiya N; Uehara Y; Iwao M
    Bioorg Med Chem; 2017 Dec; 25(24):6563-6580. PubMed ID: 29133033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.
    Hao Y; Wang X; Zhang T; Sun D; Tong Y; Xu Y; Chen H; Tong L; Zhu L; Zhao Z; Chen Z; Ding J; Xie H; Xu Y; Li H
    J Med Chem; 2016 Aug; 59(15):7111-24. PubMed ID: 27396610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of non-resistant ROS-1 inhibitors using structure based pharmacophore analysis.
    Pathak D; Chadha N; Silakari O
    J Mol Graph Model; 2016 Nov; 70():85-93. PubMed ID: 27693947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.